首页|尤瑞克林药物利用评价标准的建立与应用

尤瑞克林药物利用评价标准的建立与应用

扫码查看
目的 建立尤瑞克林药物利用评价(DUE)标准,为临床提供有效的合理用药监测方法。方法 参考尤瑞克林药品说明书、指南及相关文献,结合德尔菲法,建立尤瑞克林的DUE标准。回顾性调取2020年3月至2022年5月河南省和陕西省共3家医院使用尤瑞克林的住院患者信息,按照建立的DUE标准对其进行合理性评价。结果 DUE标准包括用药指征、用药过程和用药结果3个方面。共纳入456例患者,其中不合理的用药现象主要包括适应证不适宜(3。9%)、存在禁忌(0。7%)、用药时机不适宜(0。9%)、药物相互作用(1。8%)4个方面。结论 本研究建立的尤瑞克林DUE标准具有较好的实用性和科学性。多中心评价结果显示,临床使用尤瑞克林基本合理,但仍存在适应证不适宜等不合理现象。
Establishment and application of drug use evaluation criteria for urinary kallidinogenase
Objective To establish the drug use evaluation(DUE)criteria of urinary kallidinogenase and to provide an ef-fective and rational drug monitoring method for clinical use.Methods By referring to the drug instructions,relevant guidelines and literature,and employing the Delphi method,the urinary kallidinogenase DUE criteria was established.The DUE criteria were then applied to assess the rationality of urinary kallidinogenase for patients admitted to three hospitals in Henan Province and Shaanxi Province from March 2020 to May 2022.Results DUE criteria were established from three aspects:indications for drug use,drug use process,and drug use outcomes.A total of 456 patients were included,among which the main irratio-nal drug use phenomena included inappropriate indications(3.9%),contraindications(0.7%),inappropriate timing of medi-cation(0.9%),and drug interactions(1.8%).Conclusion The DUE criteria of urinary kallidinogenase established in this study are practical and scientific.The multi-center evaluation results showed that the clinical use of urinary kKallidinogenase is reasonable,but there are still irrational phenomena such as inappropriate indications.

urinary kallidinogenasedrug use evaluationrational drug use

刘秀梅、张萌、葛晓利、葛春丽、张进华

展开 >

河南中医药大学第五临床医学院(郑州人民医院)药学部,郑州 450003

西北大学附属医院(西安市第三医院)药剂科,西安 710018

河南省第二人民医院 药剂科,郑州 451191

福建省妇幼保健院 药剂科,福州 350001

展开 >

尤瑞克林 药物利用评价 合理用药

河南省医学科技攻关计划联合共建项目河南省重点研发与推广专项(科技攻关)

LHGJ20191090232102310194

2024

临床药物治疗杂志
北京药学会

临床药物治疗杂志

CSTPCD
影响因子:1.07
ISSN:1672-3384
年,卷(期):2024.22(5)
  • 17